Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents
CA 2312347 A1 · Owner: Hormos Medical Oy Ltd. · Inventors: Santti, Risto; Halonen, Kaija; Talo, Antti
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of an aromatase inhibitor for the manufacture of a pharmaceutical composition to be used in the treatment of i) detrusor urethral sphincter dyssynergia in men, wherein said detrusor urethral sphincter dyssynergia is urethral dysfunction which is due to decreased androgen to estrogen ratio in the patient or ii) decreased androgen to , estrogen ratio in men. Furthermore the invention also concerns a method for the in vivo investigation of the influence of a certain condition on the urinary function of male individuals using an animal model of male rodents wherein said rodents have been subjected to said condition anesthetized, provided with a pressure …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 9, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 9, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 9, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.